Abstract

Currently, no tool exists to assist doctors in estimating their patients’ risk of QT prolongation. Methadone is one of many medications which is known to prolong a patient’s QT, and which can lead to Torsades de Pointes and sudden cardiac death. The aim of the study was to design a QT prolongation risk factor assessment tool, for patients taking methadone, which would allow physicians to objectively assess a patient’s risk of QT prolongation. Following a literature review a QT prolongation risk factor assessment tool was created. An audit was then carried out to see what risk factors for QT prolongation were identified prior to use of the tool, in our practice, and then after the tool had been introduced. The introduction of a dedicated QT risk factor assessment tool led to an 61% (39/100 to 100/100) increase in the documentation of individual QT prolongation risk factors in our patients. There was a 100% (4/4) increase in the documentation of risk of QT prolongation in the patient notes, of discussion that risk with patients (4/4), and of the frequency of repeat ECGS (4/4). The introduction of such a QT prolongation risk factor assessment tool in our practice led to an increased awareness of QT prolonging medications, an improvement in the documentation of QT prolonging risk factors and a change in the culture of the practice around medication prescribing and QT prolongation. In patients who are on methadone, a QT prolongation risk factor assessment tool allows for an objective assessment of each patient’s risk of QT prolongation which then allows for measures to be put in place to monitor and address this risk.

Highlights

  • Methadone remains the gold standard treatment in opioid replacement therapy [1] with an estimated 650, 000 people currently using methadone worldwide [2]

  • Methadone has been implicated in sudden cardiac death thought to be due to the development of malignant arrythmias such as torsade’s de pointes [4]

  • Prolongation of the QT interval is the mechanism through which these malignant arrythmias occur, and this can be detected by the use of electrocardiograph (ECG) in patients [4]

Read more

Summary

Introduction

Methadone remains the gold standard treatment in opioid replacement therapy [1] with an estimated 650, 000 people currently using methadone worldwide [2]. This accounts for less than 10% of those who are in need of treatment, with 10,000 patients currently on methadone treatment in Ireland [3]. Methadone has been implicated in sudden cardiac death thought to be due to the development of malignant arrythmias such as torsade’s de pointes [4]. Prolongation of the QT interval is the mechanism through which these malignant arrythmias occur, and this can be detected by the use of electrocardiograph (ECG) in patients [4]. Irish data on this is currently lacking and due to the differences in the structures around addiction services between both nations, the American figures cannot be extrapolated to draw a conclusion on the situation in Ireland

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call